nach oben

Current Anesthesiology Reports

Erschienen in:

03.01.2024 | Anesthesia, Pain Management and Long-term Outcomes (VNR Gottumukkala and ER Mariano, Section Editors)

Anesthetic Techniques and Long-Term Oncological Outcomes

verfasst von: Jodi-Ann Oliver, Lori-Ann Oliver, Juan P. Cata, Vijaya Gottumukkala

Erschienen in: Current Anesthesiology Reports | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cancer is a leading cause of death, accounting for nearly one in six deaths worldwide. Surgery is a critical intervention in cancer care since it provides a chance of cure or can be used to relieve symptoms in patients with advanced malignancies. Anesthesia (general, regional, or local) and analgesia in any of its delivery modes play critical roles in the treatment and palliation of cancers.

Recent Findings

Experimental data demonstrate that surgery itself and anesthetics can promote the growth of micro-metastatic diseases and the seeding of circulating cancer cells, thereby facilitating cancer progression. While this theory originates from in vitro and animal studies, evidence in humans has remained controversial until recently.

Summary

In this report, we summarize current published evidence on the impact of anesthetics and opioids on cancer progression. We focus our discussion on published human studies with special emphasis on randomized controlled trials.

Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef

Tohme S, Simmons RL, Tsung A. Surgery for cancer: a trigger for metastases. Cancer Res. 2017;77(7):1548–52.PubMedPubMedCentralCrossRef

Hiller JG, et al. Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol. 2018;15(4):205–18.PubMedCrossRef

Melamed R, et al. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesthesia Analgesia. 2003;97(5):1331–1339.

Bar-Yosef S, et al. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology. 2001;94(6):1066–73.PubMedCrossRef

Yap A, et al. Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia. Can J Anaesth. 2019;66(5):546–61.PubMedCrossRef

Zhu M, et al. Isoflurane enhances the malignant potential of glioblastoma stem cells by promoting their viability, mobility in vitro and migratory capacity in vivo. Br J Anaesth. 2016;116(6):870–7.PubMedCrossRef

Xu W, et al. Propofol inhibits Wnt signaling and exerts anticancer activity in glioma cells. Oncol Lett. 2018;16(1):402–8.ADSPubMedPubMedCentral

Pang Q-Y, et al. Comparison of outcomes after breast cancer surgery between inhalational and propofol-based intravenous anaesthesia: a systematic review and meta-analysis. J Pain Res. 2021;14:2165–77.PubMedPubMedCentralCrossRef

10.

•• Wigmore TJ, Mohammed K, Jhanji S. Long-term survival for patients undergoing volatile versus IV anesthesia for cancer surgery: a retrospective analysis. Anesthesiology, 2016;124(1): 69–79. Although a retrospective study, this was a large study which after prospective matching and adjustment for known confounding factors demonstrated improved survival in patients undergoing elective cancer surgery with propofol based TIVA compared to volatile anesthesia. This biological plausibility generated great interest in the study of the effects of anesthetic agents on cancer outcomes.

11.

Makito KMK, Fushimi K, Yasunaga H. Volatile versus total intravenous anesthesia for cancer prognosis in patients having digestive cancer surgery: a nationwide retrospective cohort study. Anesthesiology. 2020;133(4):764–73.PubMedCrossRef

12.

Cao S-J, et al. Long-term survival in older patients given propofol or sevoflurane anaesthesia for major cancer surgery: follow-up of a multicentre randomised trial. Br J Anaesth. 2023;131(2):266–75.PubMedCrossRef

13.

Lovett-Carter D, et al. The effect of systemic lidocaine on post-operative opioid consumption in ambulatory surgical patients: a meta-analysis of randomized controlled trials. Perioper Med. 2021;10(1):11.CrossRef

14.

Cata JP, et al. Lidocaine stimulates the function of natural killer cells in different experimental settings. Anticancer Res. 2017;37(9):4727–32.PubMed

15.

Ramirez MF, Tran P, Cata JP. The effect of clinically therapeutic plasma concentrations of lidocaine on natural killer cell cytotoxicity. Reg Anesth Pain Med. 2015;40(1):43–8.PubMedCrossRef

16.

Galoş EV, et al. Neutrophil extracellular trapping and angiogenesis biomarkers after intravenous or inhalation anaesthesia with or without intravenous lidocaine for breast cancer surgery: a prospective, randomised trial. Br J Anaesth. 2020;125(5):712–21.PubMedCrossRef

17.

Li CY, et al. Lidocaine attenuates monocyte chemoattractant protein-1 production and chemotaxis in human monocytes: possible mechanisms for its effect on inflammation. Anesth Analg. 2003;97(5):1312–6.PubMedCrossRef

18.

Zhang H, et al. Effects of intravenous infusion of lidocaine on short-term outcomes and survival in patients undergoing surgery for ovarian cancer: a retrospective propensity score matching study. Front Oncol 2022;11:689832.

19.

Zhang H, et al. Intraoperative lidocaine infusion in patients undergoing pancreatectomy for pancreatic cancer: a mechanistic, multicentre randomised clinical trial. Br J Anaesth. 2022;129(2):244–53.PubMedCrossRef

20.

Zhang H, et al. Association between intraoperative intravenous lidocaine infusion and survival in patients undergoing pancreatectomy for pancreatic cancer: a retrospective study. British J Anaesth. 2020;125(2):141–8.CrossRef

21.

Lavon H, et al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br J Anaesth. 2018;120(1):188–96.PubMedCrossRef

22.

Chen W, et al. Dexmedetomidine provides type-specific tumour suppression without tumour-enhancing effects in syngeneic murine models. Br J Anaesth. 2023;130(2):142–53.PubMedCrossRef

23.

Cata J, et al. Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery. J Anaesthesiol Clin Pharmacol. 2017;33(3):317–23.PubMedPubMedCentralCrossRef

24.

Hu J, et al. Association between intraoperative dexmedetomidine and all-cause mortality and recurrence after laparoscopic resection of colorectal cancer: follow-up analysis of a previous randomized controlled trial. Front Oncol 2023;13:906514.

25.

Xing M-W, et al. Effect of intraoperative dexmedetomidine on long-term survival in older patients after major noncardiac surgery: 3-year follow-up of a randomized trial. J Clin Anesthesia 2023;86.

26.

Connolly JG, et al. Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. Br J Anaesth. 2021;127(1):75–84.PubMedPubMedCentralCrossRef

27.

Forget P, et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg. 2010;110(6):1630–5.PubMedCrossRef

28.

Cho JS, et al. The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. Canadian J Anesthesia/J Canadien d'Anesthésie. 2021;68(5):683–92.CrossRef

29.

•• Sessler DI, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. Lancet 2019;394(10211): 1807–1815. This was the first large multicenter randomized controlled trial performed to evaluate the effect of regional anesthesia-analgesia with paravertebral blocks and propofol sedation on recurrence rates after breast cancer surgery.

30.

Xu Z-Z, et al. Epidural anesthesia–analgesia and recurrence-free survival after lung cancer surgery: a randomized trial. Anesthesiology. 2021;135(3):419–32.PubMedCrossRef

31.

Aloia TA, et al. A randomized controlled trial of postoperative thoracic epidural analgesia versus intravenous patient-controlled analgesia after major hepatopancreatobiliary surgery. Ann Surg. 2017;266(3):545–54.PubMedCrossRef

32.

Vicente D, et al. Impact of epidural analgesia on the systemic biomarker response after hepatic resection. Oncotarget. 2019;10(5):584–94.PubMedPubMedCentralCrossRef

33.

Xing W, et al. Lidocaine induces apoptosis and suppresses tumor growth in human hepatocellular carcinoma cells in vitro and in a xenograft model in vivo. Anesthesiology. 2017;126(5):868–81.PubMedCrossRef

34.

Sessler DI. Does regional analgesia reduce the risk of cancer recurrence? A hypothesis. Eur J Cancer Prev. 2008;17(3):269–72.PubMedCrossRef

35.

Illias AM, et al. Association of regional anesthesia with oncological outcomes in patients receiving surgery for bladder cancer: a meta-analysis of observational studies. Front Oncol 2023;13:1097637.

36.

Cata JP, et al. The impact of paravertebral block analgesia on breast cancer survival after surgery. Reg Anesth Pain Med. 2016;41(6):696–703.PubMedCrossRef

37.

Exadaktylos AK, et al. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105(4):660–4.PubMedCrossRef

38.

Christopherson R, et al. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg. 2008;107(1):325–32.PubMedCrossRef

39.

Myles PS, et al. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ. 2011;342: d1491.PubMedCrossRef

40.

Yu L, et al. Perioperative pectoral nerve block type II and postoperative recurrence in breast cancer: a randomized controlled trial. BMC Surg. 2022;22(1):447.PubMedPubMedCentralCrossRef

41.

Karmakar MK, et al. Survival analysis of patients with breast cancer undergoing a modified radical mastectomy with or without a thoracic paravertebral block: a 5-year follow-up of a randomized controlled trial. Anticancer Res. 2017;37(10):5813–20.MathSciNetPubMed

42.

Du YT, et al. Long-term survival after combined epidural-general anesthesia or general anesthesia alone: follow-up of a randomized trial. Anesthesiology. 2021;135(2):233–45.PubMedCrossRef

43.

Falk W, et al. Comparison between epidural and intravenous analgesia effects on disease-free survival after colorectal cancer surgery: a randomised multicentre controlled trial. Br J Anaesth. 2021;127(1):65–74.PubMedPubMedCentralCrossRef

44.

Badwe RA, et al. Effect of peritumoral infiltration of local anesthetic before surgery on survival in early breast cancer. J Clin Oncol. 2023;41(18):3318–28.PubMedCrossRef

45.

Gorur A, et al. Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma. Life Sci. 2021;278:119541.PubMedCrossRef

46.

Cata JP, et al. The µ‐opioid receptor in cancer and its role in perineural invasion: a short review and new evidence. Adv Biol 2022;2200020.

47.

Zylla D, et al. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth. 2014;113:i109–16.PubMedPubMedCentralCrossRef

48.

Zylla D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013;119(23):4103–10.PubMedCrossRef

49.

Zhang H, et al. Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma. Br J Anaesth. 2020;125(5):722–9.PubMedCrossRef

50.

Zhang H, et al. Association of mu-opioid receptor(MOR) expression and opioids requirement with survival in patients with stage I-III pancreatic ductal adenocarcinoma. Front Oncol. 2021;11: 686877.PubMedPubMedCentralCrossRef

51.

Diaz-Cambronero O, et al. Mu opioid receptor 1 (MOR-1) expression in colorectal cancer and oncological long-term outcomes: a five-year retrospective longitudinal cohort study. Cancers (Basel). 2020;12(1):134.PubMedCrossRef

52.

Paice JA, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(27):3325–45.PubMedCrossRef

53.

Cata JP, et al. Intraoperative opioids use for laryngeal squamous cell carcinoma surgery and recurrence: a retrospective study. J Clin Anesth. 2015;27(8):672–9.PubMedCrossRef

54.

Cata JP, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med. 2014;3(4):900–8.PubMedPubMedCentralCrossRef

55.

Nelson DB, et al. Persistent opioid use is associated with worse survival after lobectomy for stage i non-small cell lung cancer. Pain. 2019;160(10):2365–73.PubMedCrossRef

56.

Steele GL, et al. Impact of pain, opioids, and the mu-opioid receptor on progression and survival in patients with newly diagnosed stage IV pancreatic cancer. Am J Clin Oncol. 2020;43:591–7.PubMedCrossRef

57.

Cronin-Fenton D. Opioids and breast cancer recurrence. Curr Opin Support Palliat Care. 2019;13(2):88–93.PubMedCrossRef

58.

Patino MA, et al. The impact of intraoperative opioid use on survival after oral cancer surgery. Oral Oncol. 2017;74:1–7.PubMedCrossRef

59.

Owusu-Agyemang P, et al. Assessing the survival impact of perioperative opioid consumption in children and adolescents undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Paediatr Anaesth. 2017;27(6):648–56.PubMedCrossRef

60.

Janku F, et al. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016;27(11):2032–8.PubMedPubMedCentralCrossRef

61.

Vijayakumar J, et al. An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer. Invest New Drugs. 2022;41(1):70–5.PubMedPubMedCentralCrossRef

Titel: Anesthetic Techniques and Long-Term Oncological Outcomes
verfasst von: Jodi-Ann Oliver
Lori-Ann Oliver
Juan P. Cata
Vijaya Gottumukkala
Publikationsdatum: 03.01.2024
Verlag: Springer US
Erschienen in: Current Anesthesiology Reports / Ausgabe 1/2024
Elektronische ISSN: 2167-6275
DOI: https://doi.org/10.1007/s40140-023-00605-w

Neu im Fachgebiet AINS

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Anesthetic Techniques and Long-Term Oncological Outcomes